Oorsprong van het eerstegraads netwerk van Lars Dreiøe
| Entiteit | Type entiteit | Industrie | |
|---|---|---|---|
| Public Company | Pharmaceuticals: Major | 29 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Lars Dreiøe via zijn persoonlijke netwerk
| Onderneming | Sector | Gelieerde personen | Hoofdpost |
|---|---|---|---|
| BAXTER INTERNATIONAL INC. | Medical Specialties | Sales & Marketing | |
| BIOCRYST PHARMACEUTICALS, INC. | Biotechnology | Director/Board Member | |
| IONIS PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Medical Specialties | Corporate Officer/Principal Corporate Officer/Principal | |
| AMICUS THERAPEUTICS, INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Janssen Pharmaceuticals, Inc.
 Janssen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Janssen Pharmaceuticals, Inc. develops and markets prescription drugs in various therapeutic areas, including attention deficit hyperactivity disorder, pain management, acid reflux and infectious diseases, women’s health, and mental health (bipolar I disorder and schizophrenia); and neurologic, including Alzheimer’s disease, epilepsy, and migraine prevention and treatment. Its products include Axert, Darzalezx, Invokamet XR, Invokana, Remicade, Reopro, and Risperdal Consta. The company was founded by Paul Janssen in 1953 and is headquartered in Titusville, NJ. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| SHIRE | Pharmaceuticals: Major | Corporate Officer/Principal | |
Gambro AB
 Gambro AB Medical SpecialtiesHealth Technology Gambro AB engages in the development and manufacturing of dialysis equipment and blood purification products. It provides products and therapies for kidney and liver dialysis, myeloma kidney therapy, and other extracorporeal therapies for chronic and acute patients. The firm offers products for hemodialysis, acute care, myeloma kidney therapy, and vascular access and water systems. The company was founded by Holger Crafoord in 1964 and is headquartered in Lund, Sweden. | Medical Specialties | Director/Board Member Public Communications Contact Chief Executive Officer | |
| KARO PHARMA AB (PUBL) | Pharmaceuticals: Major | Chairman Director of Finance/CFO | |
| MEDA AB | Pharmaceuticals: Major | Director of Finance/CFO Investor Relations Contact Director/Board Member | |
| BIOTAGE AB | Medical Specialties | Director of Finance/CFO | |
AstraZeneca AB
 AstraZeneca AB Miscellaneous Commercial ServicesCommercial Services AstraZeneca AB engages in biopharmaceutical business. It provides treatment of diseases in cardiovascular and metabolic diseases, cancer, respiratory, inflammation, and autoimmunity. The firm offers operations in the areas of infection, neuroscience, and stomach and intestinal diseases. The company was founded in 1999 and is headquartered in Sodertalje, Sweden. | Miscellaneous Commercial Services | Corporate Officer/Principal Director/Board Member | |
| George Washington University | College/University | Masters Business Admin | |
| RECIPHARM AB (PUBL) | Biotechnology | Director of Finance/CFO Public Communications Contact | |
| ALNYLAM PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Roche Diagnostics GmbH
 Roche Diagnostics GmbH Miscellaneous Commercial ServicesCommercial Services Part of Roche Holding AG, Roche Diagnostics GmbH is a German company that develops innovative medicines, treatments, and diagnostics. The company is based in Mannheim, Germany. The CEOs of the company are Claudia Fleischer, Claus Haberda, Clemens Schmid. Roche Diagnostics was acquired by Roche Holding AG on January 01, 1999. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
| University of Maryland | College/University | Undergraduate Degree | |
| University of Uppsala | College/University | Undergraduate Degree | |
| ONCOPEPTIDES AB | Pharmaceuticals: Major | Investor Relations Contact | |
| CALLIDITAS THERAPEUTICS AB | Pharmaceuticals: Major | Director/Board Member Chief Tech/Sci/R&D Officer | |
| Coventry University | College/University | Undergraduate Degree | |
| CAMURUS AB | Pharmaceuticals: Major | Director/Board Member | |
| University of Lund | College/University | Graduate Degree Undergraduate Degree | |
Takeda A/S
 Takeda A/S Financial ConglomeratesFinance Takeda A/S engages in holding or owning of securities in other companies other than banks. The company was founded on January 4, 2005 and is headquartered in Taastrup, Denmark. | Financial Conglomerates | Chief Executive Officer Chief Operating Officer | |
| VIVESTO AB | Pharmaceuticals: Generic | Director/Board Member | |
Takeda Pharmaceuticals International AG
 Takeda Pharmaceuticals International AG Pharmaceuticals: MajorHealth Technology Takeda Pharmaceuticals International GmbH develops, manufactures, and distributes pharmaceutical products. It offers medicines in therapeutic areas, such as, cardiovascular and metabolic, oncology, central nervous system, respiratory and immunology, general medicine, and vaccines. The firm also provides packaging, development, contract manufacturing and quality control services. Takeda Pharmaceuticals International was founded in 1874 and is headquartered in Zurich, Switzerland. | Pharmaceuticals: Major | President Corporate Officer/Principal | |
OxThera AB
 OxThera AB Pharmaceuticals: GenericHealth Technology OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden. | Pharmaceuticals: Generic | Director of Finance/CFO | |
| Harvard Medical School | College/University | Doctorate Degree Graduate Degree | |
Nycomed AB
 Nycomed AB Pharmaceuticals: MajorHealth Technology Nycomed AB With a broad portfolio of products and a powerful pipeline, they work in a wide range of therapeutic areas, particularly cardiology, gastroenterology, osteoporosis, respiratory, and pain and tissue management. Nycomed engaged in all aspects of a product's life, from research and development to customer relations. They also work closely with innovative research-based companies, constantly looking for products with real promise for patients. They believe that everything do matters to someone. So they work carefully to make sure they get what they do right. They focus on results and respond quickly to the needs of patients and healthcare providers, giving them the best possible experience from working with clients. By doing this, they can achieve vision of being the preferred pharmaceutical company. | Pharmaceuticals: Major | Chief Executive Officer Corporate Officer/Principal General Counsel | |
| ADVICENNE | Pharmaceuticals: Generic | Corporate Officer/Principal | |
| Medical University Sofia | College/University | Doctorate Degree | |
| PROQR THERAPEUTICS N.V. | Pharmaceuticals: Major | Director/Board Member | |
Sanofi AB
 Sanofi AB Medical DistributorsDistribution Services Part of Sanofi, Sanofi AB is a pharmaceutical company based in Stockholm, Sweden. The Swedish company's description states that it is an international pharmaceutical company. | Medical Distributors | Corporate Officer/Principal | |
Freeline Therapeutics Ltd.
 Freeline Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Freeline Therapeutics Ltd. operates as a biopharmaceutical company, which develops gene therapies for bleeding and other debilitating disorders. The company was founded by Chris Hollowood in 2015 and is headquartered in London, the United Kingdom. | Pharmaceuticals: Major | Chief Executive Officer | |
| DOVA PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member President | |
Alnylam Germany GmbH
 Alnylam Germany GmbH BiotechnologyHealth Technology Part of Alnylam Pharmaceuticals, Inc., Alnylam Germany GmbH is a company that is leading the translation of RNA Interference (RNAi) into a completely innovative class of medicines, which they believe have the potential to transform the lives of patients with genetic and rare diseases. The company is based in Munich, Germany. The CEOs of the company are David Ronald Jones, Hannes Schmeil, Theresa Marie Heggie. The text in the company's description is in German, but it appears to emphasize the importance of clinical trials in developing new medicines and highlights the company's use of RNAi technology to help patients with limited treatment options. | Biotechnology | Chief Executive Officer | |
Alnylam UK Ltd.
 Alnylam UK Ltd. BiotechnologyHealth Technology Founded in 2002, Alnylam UK Ltd. is a subsidiary of Alnylam Pharmaceuticals, Inc. that develops biotechnology products. The company is based in Maidenhead, UK. | Biotechnology | Director/Board Member | |
| INFLARX N.V. | Biotechnology | Director/Board Member | |
| GENERATION BIO CO. | Pharmaceuticals: Major | Director/Board Member Chief Executive Officer | |
U-R-Not Ltd.
 U-R-Not Ltd. Miscellaneous Commercial ServicesCommercial Services U-R-Not Ltd. provides other service activities. | Miscellaneous Commercial Services | Director/Board Member | |
Swedish Orphan Biovitrum, Inc.
 Swedish Orphan Biovitrum, Inc. Pharmaceuticals: MajorHealth Technology Swedish Orphan Biovitrum, Inc. operates as an international rare disease company providing access to treatments that make a significant difference for people with rare diseases. Its business areas include haemophilia, immunology and specialty care. The company is headquartered in Waltham, MA. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member | |
| Oslo Metropolitan University | College/University | Undergraduate Degree | |
| Ullevaal School of Bioengineering | College/University | Undergraduate Degree | |
| Belnor BVBA | Founder | ||
| Arden Regulatory Clinical & Medical Consulting Ltd. | Director/Board Member | ||
| FREELINE THERAPEUTICS HOLDINGS PLC | Biotechnology | Chief Executive Officer | |
| Jane Goddall Institute Belgium | Director/Board Member |
Statistieken
Internationaal
| Zweden | 19 |
| Verenigde Staten | 14 |
| Verenigd Koninkrijk | 7 |
| Duitsland | 4 |
| Noorwegen | 3 |
Sectoraal
| Health Technology | 33 |
| Consumer Services | 10 |
| Commercial Services | 5 |
| Finance | 2 |
| Distribution Services | 2 |
Operationeel
| Director/Board Member | 120 |
| Corporate Officer/Principal | 60 |
| Independent Dir/Board Member | 47 |
| Chairman | 34 |
| Chief Executive Officer | 26 |
Sterkste connecties
| Insiders | |
|---|---|
| Sven Håkan Björklund | 46 |
| Bo Jesper Hansen | 34 |
| Jeff Jonas | 21 |
| Guido Oelkers | 19 |
| Alan Henry Raffensperger | 17 |
| Lena Elisabeth Svanberg | 16 |
| Theresa Heggie | 16 |
| Henrik Stenqvist | 16 |
| An van Es-Johansson | 13 |
| Cameron McDonough | 11 |
| Hege Hellstrom | 11 |
| Per Richard Torbjörn Hallberg | 10 |
| Paula Treutiger | 9 |
| Holly May | 8 |
| Milan Zdravkovic | 7 |
- Beurs
- Insiders
- Lars Dreiøe
- Bedrijfsconnecties
